Combination treatment for kidney disease in obesity
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether taking two medications together—finerenone and semaglutide—can help protect kidney function in people with obesity and chronic kidney disease who have protein in their urine. The goal is to see if this combination is safe and effective for slowing kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have obesity, defined by a high BMI (28 or more) and a high waist-to-height ratio, or a high body fat percentage (25% for men, 30% for women).
- You have chronic kidney disease with protein in your urine (a urine test showing UACR between 100 and 3500 mg/g).
- Your kidney function (eGFR) is at least 25 mL/min/1.73 m² and has been stable recently.
- You do not have diabetes (type 1 or type 2) and your blood sugar levels are normal.
- You have not taken certain medications for kidney or heart conditions in the past 8 weeks (like spironolactone or semaglutide).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two experimental treatments—one that reduces protein in urine and another that may help control blood sugar and weight—for people with chronic kidney disease. It aims to find safer, more effective ways to slow kidney damage.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
This trial tests a medication called finerenone to see if it can lower the amount of protein in your urine, which is a sign of kidney damage. It is for people with type 2 diabetes and chronic kidney disease who are already on standard blood pressure medications.
This study tests whether combining two medications, finerenone and empagliflozin, can lower blood pressure in people with obesity and high blood pressure. It may offer a new option for managing both conditions together.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
Hear when a new Obesity; Chronic Kidney Disease; Albuminuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.